In Alzheimer's disease, most therapy approaches fail at a fundamental problem: the brain cannot clear toxic amyloid-beta protein on its own. An international research team led by the Institute for Bioengineering of Catalonia (IBEC) in Barcelona succeeded in animal studies at restoring this transport mechanism. Three injections were enough to remove 50 to 60 percent of Alzheimer's deposits from the brain, and older mice thereafter behaved cognitively like healthy young animals. The study was published in October 2025 in the journal Signal Transduction and Targeted Therapy (DOI: 10.1038/s41392-025-02426-1).
A Different Approach: Repair the Blood-Brain Barrier
Most Alzheimer's therapies target amyloid-beta, a protein that accumulates as toxic plaques in Alzheimer's brains. The IBEC team, working with West China Hospital at Sichuan University, University College London, and the University of Barcelona, chose a different path: instead of attacking amyloid-beta directly, the nanoparticles restored the blood-brain barrier.
This barrier is a biological wall separating the brain from the bloodstream. It possesses specific transport systems, including the LRP1 receptor, which actively removes amyloid-beta from the brain. In Alzheimer's patients, this transport mechanism is disrupted. The supramolecular nanoparticles of the IBEC team are themselves bioactive, according to the study; they do not merely serve as carriers for other drugs, but activate the LRP1 receptor directly and restore the brain's natural clearance function.
The Results: Rapid, Pronounced, Sustained
In genetically modified mice that overproduce amyloid-beta, the nanoparticles reduced brain concentration of this protein by 50 to 60 percent within one hour of injection. Simultaneously, amyloid-beta levels in blood plasma rose eightfold: the protein was shunted from the brain into the bloodstream and cleared. The treatment protocol required only three injections.
Long-term effects were remarkable, according to the study. A twelve-month-old mouse, roughly equivalent to a sixty-year-old human with already-present cognitive decline, behaved like a healthy young mouse after six months of observation. Cognitive performance, measured by maze tests and other behavioral parameters, had matched that of healthy animals.
Compared to Current Alzheimer's Therapies
Currently approved anti-amyloid antibodies target amyloid-beta as well, but via different mechanisms and weaker effects. Lecanemab, FDA-approved since 2023, slowed cognitive decline in early Alzheimer's patients by 27 percent, measured on the clinical CDR-SB scale. Donanemab, currently in FDA review, slowed decline by 35 percent in Phase III studies. Both medications require regular infusions over months and cause brain edema and microhemorrhages in some patients, requiring frequent MRI monitoring.
The IBEC nanoparticles showed dramatically sharper amyloid-beta reduction in mouse models with just three injections instead of continuous therapy. Another comparison: the Alzheimer's Research Consortium CTAD estimated in 2024 that anti-amyloid therapies at best slow cognitive decline but do not reverse it. The IBEC approach, which demonstrated actual reversal in mice, conceptually reaches further.
Three Hurdles Before Clinical Practice
That the approach is fundamentally novel and effective in animal studies does not mean it will work in humans. The organization Alzheimer Research UK has repeatedly noted that over 99 percent of Alzheimer's drugs promising in animal studies have failed in human clinical trials. Mouse models do not fully capture the heterogeneity of human Alzheimer's disease.
Three concrete conditions must be met for the therapy to succeed in humans. First, the safety of the nanoparticles in the human body must be established: supramolecular particles of this type have not previously been tested in humans; unknown immune reactions or long-term tissue accumulation could be problematic. Second, efficacy must be replicated in clinical trials. Third, the treatment timing must be right: in mice, nanoparticles were administered at an early stage. Whether therapy works in advanced damage, when neuronal structures are already irreversibly destroyed, remains open.
The IBEC team has stated clinical trials in humans as the next step but has not published a concrete timeline. For novel nanoparticle therapies, given regulatory requirements, a realistic timeframe to possible approval is five to ten years.